
Organokines in COVID-19: A Systematic Review
2023; Multidisciplinary Digital Publishing Institute; Volume: 12; Issue: 10 Linguagem: Inglês
10.3390/cells12101349
ISSN2073-4409
AutoresSandra Maria Barbalho, Giulia Minniti, Vitor Fernando Bordin Miola, Jesselina Francisco dos Santos Haber, Patrícia Cincotto dos Santos Bueno, Luíza Santos de Argollo Haber, Raul José Silva Gírio, Cláudia Rucco Penteado Detregiachi, Camila Dall’Antonia, Victória Dogani Rodrigues, Claudia C. T. Nicolau, Virgínia Maria Cavallari Strozze Catharin, Adriano Cressoni Araújo, Lucas Fornari Laurindo,
Tópico(s)Adipokines, Inflammation, and Metabolic Diseases
ResumoCoronavirus disease 2019 (COVID-19) is a viral infection caused by SARS-CoV-2 that induces a generalized inflammatory state. Organokines (adipokines, osteokines, myokines, hepatokines, and cardiokines) can produce beneficial or harmful effects in this condition. This study aimed to systematically review the role of organokines on COVID-19. PubMed, Embase, Google Scholar, and Cochrane databases were searched, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed, and 37 studies were selected, comprising more than 2700 individuals infected with the virus. Among COVID-19 patients, organokines have been associated with endothelial dysfunction and multiple organ failure due to augmented cytokines and increased SARS-CoV-2 viremia. Changes in the pattern of organokines secretion can directly or indirectly contribute to aggravating the infection, promoting immune response alterations, and predicting the disease progression. These molecules have the potential to be used as adjuvant biomarkers to predict the severity of the illness and severe outcomes.
Referência(s)